JPMorgan lowered the firm’s price target on 3M to $110 from $118 and keeps a Neutral rating on the shares. The new target reflects reflect the remaining company post the healthcare spin, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
